A Bivalent Nanoparticle Vaccine Exhibits Potent Cross-protection Against the Variants of SARS-CoV-2

Overview

Journal Cell Rep

Publisher Cell Press

Specialties Biology
Cell Biology
Molecular Biology

Date 2022 Jan 6

PMID 34990583

Citations 18

Authors

Yaochang Yuan

Xiantao Zhang

Ran Chen

Yuzhuang Li

Bolin Wu

Rong Li

Fan Zou

Xiancai Ma

Xuemei Wang

Qier Chen

Jieyi Deng

Yongli Zhang

Tao Chen

Yingtong Lin

Shumei Yan

Xu Zhang

Congrong Li

Xiuqing Bu

Yi Peng

Changwen Ke

Kai Deng

Ting Pan

Xin He

Yiwen Zhang

Hui Zhang

Affiliations

Soon will be listed here.

Abstract

Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.

Citing Articles

Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.

Yang K, Zeng Y, Wu X, Li J, Guo J Front Immunol. 2024; 15:1392898.

PMID: 39351240 PMC: 11440195. DOI: 10.3389/fimmu.2024.1392898.

Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.

Zhang Y, Chen A, Li D, Yuan Q, Zhu A, Deng J NPJ Vaccines. 2024; 9(1):176.

PMID: 39341822 PMC: 11438966. DOI: 10.1038/s41541-024-00971-4.

Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia.

Fang Q, Lu X, Zhu Y, Lv X, Yu F, Ma X Cell Rep Med. 2024; 5(6):101614.

PMID: 38897173 PMC: 11228807. DOI: 10.1016/j.xcrm.2024.101614.

The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis.

He X, Zhang X, Wu B, Deng J, Zhang Y, Zhu A Nat Immunol. 2024; 25(4):622-632.

PMID: 38454157 DOI: 10.1038/s41590-024-01776-2.

Omicron and Delta variant prevalence detection and identification during the fourth COVID-19 wave in Mexico using wastewater-based epidemiology.

Aguayo-Acosta A, Oyervides-Munoz M, Rodriguez-Aguillon K, Ovalle-Carcano A, Romero-Castillo K, Robles-Zamora A IJID Reg. 2023; 10:44-51.

PMID: 38149263 PMC: 10750064. DOI: 10.1016/j.ijregi.2023.11.005.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

Hoffmann M, Arora P, Gross R, Seidel A, Hornich B, Hahn A . SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021; 184(9):2384-2393.e12. PMC: 7980144. DOI: 10.1016/j.cell.2021.03.036. View

Arunachalam P, Walls A, Golden N, Atyeo C, Fischinger S, Li C . Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021; 594(7862):253-258. DOI: 10.1038/s41586-021-03530-2. View

Kreier F . 'Unprecedented achievement': who received the first billion COVID vaccinations?. Nature. 2021; . DOI: 10.1038/d41586-021-01136-2. View

Wu K, Choi A, Koch M, Elbashir S, Ma L, Lee D . Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine. 2021; 39(51):7394-7400. PMC: 8572694. DOI: 10.1016/j.vaccine.2021.11.001. View

Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F . Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021; 27(5):917-924. DOI: 10.1038/s41591-021-01318-5. View

Letko M, Marzi A, Munster V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4):562-569. PMC: 7095430. DOI: 10.1038/s41564-020-0688-y. View

Saunders K, Lee E, Parks R, Martinez D, Li D, Chen H . Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021; 594(7864):553-559. PMC: 8528238. DOI: 10.1038/s41586-021-03594-0. View

10.

Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer A, Ginn H . Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021; 184(9):2348-2361.e6. PMC: 7901269. DOI: 10.1016/j.cell.2021.02.037. View

11.

Zhang J, Huang F, Xia B, Yuan Y, Yu F, Wang G . The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. Signal Transduct Target Ther. 2021; 6(1):189. PMC: 8113286. DOI: 10.1038/s41392-021-00604-5. View

12.

Ramanathan M, Ferguson I, Miao W, Khavari P . SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis. 2021; 21(8):1070. PMC: 8133765. DOI: 10.1016/S1473-3099(21)00262-0. View

13.

Li R, Liu J, Zhang H . The challenge of emerging SARS-CoV-2 mutants to vaccine development. J Genet Genomics. 2021; 48(2):102-106. PMC: 8056881. DOI: 10.1016/j.jgg.2021.03.001. View

14.

Wang P, Nair M, Liu L, Iketani S, Luo Y, Guo Y . Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021; 593(7857):130-135. DOI: 10.1038/s41586-021-03398-2. View

15.

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

16.

Walls A, Fiala B, Schafer A, Wrenn S, Pham M, Murphy M . Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell. 2020; 183(5):1367-1382.e17. PMC: 7604136. DOI: 10.1016/j.cell.2020.10.043. View

17.

Edara V, Pinsky B, Suthar M, Lai L, Davis-Gardner M, Floyd K . Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J Med. 2021; 385(7):664-666. PMC: 8279090. DOI: 10.1056/NEJMc2107799. View

18.

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

19.

Brouwer P, Brinkkemper M, Maisonnasse P, Dereuddre-Bosquet N, Grobben M, Claireaux M . Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell. 2021; 184(5):1188-1200.e19. PMC: 7834972. DOI: 10.1016/j.cell.2021.01.035. View

20.

Huang Q, Ji K, Tian S, Wang F, Huang B, Tong Z . A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat Commun. 2021; 12(1):776. PMC: 7858593. DOI: 10.1038/s41467-021-21037-2. View